--- title: "Dow 30 Earnings: Merck Fourth Quarter Fiscal 2017" description: Dow 30, fourth-quarter earnings, Merck & Co., GAAP loss of $0.32 a share, $2.6 billion tax-related charge, higher revenues, 56% reduction in R&D expenses image: https://investor.valueline.com/hubfs/VL%20Blog%20Images/iStock-506712124.jpg --- [![The Value Line Blog](https://investor.valueline.com/hubfs/VL%20Blog%20Images/vl_blog_header.png)](https://investor.valueline.com/blog) [Stock Highlights](https://investor.valueline.com/blog/topic/stock-highlights) # Dow 30 Earnings: Merck Fourth Quarter Fiscal 2017 February 2, 2018 New Jersey-based drugmaker **Merck & Co**. ([MRK](https://research.valueline.com/research#sym=MRK&list=dow30&sec=company) – [Free Merck Stock Report](https://research.valueline.com/api/report?documentID=2185-VL_20171006_VLIS_MRK_2009_01-37CRAE3ALGJEDAGCLJDQRLLAR5&symbol=MRK)) has reported a third-quarter GAAP loss of $0.02 a share, versus $0.78 in the comparable period of 2016. The sharp year-over-year decline in profits can be primarily attributed to a $2.35 billion charge related to the formation of an oncology collaboration with AstraZeneca (see below), and to a lesser extent reduced revenues (-2%). Meantime, adjusted earnings, which exclude one-time gains, charges, and other nonrecurring items, and are more closely followed by Wall Street, came in at $1.11 a share, versus $1.07 in 2016. The adjusted figure beat consensus expectations of $1.03 a share (and our $1.02 estimate), but revenues were a bit light due in part to the NotPetya cyber attack in the second quarter, which disrupted the company's manufacturing operations. While management raised its full-year GAAP earnings guidance to $1.78-$1.84 (previously $1.60-$1.72) and its adjusted range to $3.91-$3.97 a share (previously $3.76-$3.88), shares of MRK were trading 4%-5% lower on the release. In the September period, worldwide revenues dipped 2% year over year, to $10.33 billion. Management indicated that the aforementioned cyber attack cost the company roughly $135 million in sales, but results were also hurt by reductions in several key products. Merck's top-grossing *JANUVIA/JANUMET *franchise (15% of total revenue) saw its sales decline 2% due to pricing pressure, while #3 seller *GARDASIL*plummeted 22%, owing to weakness in the United States. Continued generic erosion in* ZETIA/VYTORIN *(-51%) and *REMICADE* (-31%) were also significant drags. On a positive note, the company's standout immuno-oncology asset *KEYTRUDA* further exhibited strong momentum (+194%), as did Hep-C drug*ZEPATIER *(+185%). Strength in the animal health business (+16%) provided additional support. Management raised its full-year revenue outlook slightly, from $39.4 billion-$40.4 billion, to $40.0 billion-$40.5 billion. On July 27th, Merck struck a deal with AstraZeneca to co-develop and co-commercialize one of Astra's most-promising oncology assets, *LYNPARZA*. The drug's pipeline has grown considerably in recent years, with 14 indications currently being developed across several tumor types, including breast, prostate, and pancreatic cancers. Astra is hopeful that Merck's broad development of* KEYTRUDA *could help maximize the potential of *LYNPARZA*, and was willing to give up half of the drug's future sales to find out. While Merck will shoulder a big portion of the near-term costs, the payoff could be substantial. Under the terms, Merck agreed to pay up to $8.5 billion in total consideration, including $1.6 billion upfront. Merck's long-term growth story remains heavily tied to the continued development and success of its oncology program, specifically immunotherapy asset *KEYTRUDA*. The drug surpassed the $1 billion sales mark in the third quarter and currently represents the company's second-largest revenue generator (10% of total sales). *KEYTRUDA* has already racked up regulatory approvals for a wide range of indications, and development efforts are ongoing. Current estimates suggest the drug could top $8 billion in annual sales by 2021. All told, we continue to view MRK as a solid core holding for investors seeking participation in the large pharma space. An above-average dividend yield and superior grades for Safety (1) and Financial Strength (A++) should appeal to risk-averse, income-oriented accounts. Moreover, the recent pullback has provided a more favorable entry point. **About The Company**: [Merck & Co.](http://www.valueline.com/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=9698) is an international developer, manufacturer, and distributor of pharmaceuticals. Important product names include *JANUVIA/JANUMET *(type-2 diabetes); *ZETIA/VYTORIN *(hypercholesterolemia); *GARDASIL* (vaccine); *KEYTRUDA* (lung cancer); and *REMICADE* (arthritis). In 2014, the company made three significant acquisitions: Schering-Plough (January), Idenix Pharmaceuticals (June), and Cubist Pharmaceuticals (December). — Michael Ratty *At the time of this article’s writing, the author did not have positions in any of the companies mentioned.* [![Register now for our free One Stock to Buy webinar](https://no-cache.hubspot.com/cta/default/2532383/5a80130b-f0ce-4bd8-acbd-f077f2232ec5.png)](https://cta-redirect.hubspot.com/cta/redirect/2532383/5a80130b-f0ce-4bd8-acbd-f077f2232ec5) ### Popular Posts Search Search Blog ### Topics - [Investing 101 (2)](https://investor.valueline.com/blog/topic/investing-101) - [Market Commentary (37)](https://investor.valueline.com/blog/topic/market-commentary) - [Stock Highlights (390)](https://investor.valueline.com/blog/topic/stock-highlights) - [Stock Market Today (2071)](https://investor.valueline.com/blog/topic/stock-market-today) Copyright 2026 Value Line, Inc. All Rights Reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. VALUE LINE IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN OR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. This blog is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product. Officers, directors, or employees of Value Line, Inc. and its affiliates and subsidiaries, and EULAV Asset Management, may own stocks that are featured in this email. Nothing herein should be construed as an offer to buy or sell securities or to give individual investment advice. Value Line, the Value Line logo, The Most Trusted Name in Investment Research, “Smart research. Smarter investing.”, The Value Line Investment Survey, Timeliness, and Safety are trademarks or registered trademarks of Value Line, Inc. and/or its affiliates in the United States and other countries.